State-of-the-art imaging of prostate cancer

Marko, Jamie; Gould, C. Frank; Bonavia, Grant; Wolfman, Darcy J.

doi:10.1016/j.urolonc.2015.05.015

Cited by 14 publications

(17 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systematic comparison of 64 CuCl 2 uptake in a panel of PCa cell lines and in an immortalized epithelial cell line used to study benign hyperplasia [ 32 ] revealed that PCa cells exhibited, in general, higher 64 Cu uptake than non-tumoral cells. This observation provides a cellular framework to the observation that 64 CuCl 2 provides images with a very good contrast between malignant lesions and the adjacent non-diseased tissue, which is a limitation of some of the current imaging techniques in use for PCa diagnosis [ 5 , 31 , 33 ].…”

Section: Discussionmentioning

confidence: 94%

“…Despite being one of the most commonly used positron emission tomography (PET) tracers in oncology, 18 F-Fludeoxyglucose has limited sensitivity for the detection of primary PCa and recurrent disease [ 4 ]. Currently, 99m Tc-methylene diphosphonate bone scintigraphy is the standard method used to detect bone metastases, while 18 F-choline and 11 C-choline PET offer high sensitivity and specificity to detect lymph node involvement and distant metastases, as well as disease recurrence, being well established tracers for those purposes [ 4 , 5 ]. 68 Ga-prostate-specific membrane antigen targeted radiopharmaceuticals, which are designed to recognize a membrane glycoprotein that is highly expressed in human PCa cells, have also emerged as having tremendous potential for the detection and re-staging of PCa after biochemical recurrence, offering superior contrast and sensitivity than 18 F-choline [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…68 Ga-prostate-specific membrane antigen targeted radiopharmaceuticals, which are designed to recognize a membrane glycoprotein that is highly expressed in human PCa cells, have also emerged as having tremendous potential for the detection and re-staging of PCa after biochemical recurrence, offering superior contrast and sensitivity than 18 F-choline [ 4 ]. However, despite the availability of these probes which have proven to be valuable tools for the management of PCa, the imaging role of PET has been limited, particularly in primary PCa and disease recurrence detection, by variable accuracy of the radiotracers in discriminating cancer from normal prostate tissue or benign hyperplasia [ 4 , 5 , 6 ]. Current therapeutic alternatives to treat castration-resistant PCa include the use of chemotherapy, novel hormone therapies targeting androgen signaling, and the use of the radionuclide radium-223 for bone pain palliation [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Radiobiological Characterization of 64CuCl2 as a Simple Tool for Prostate Cancer Theranostics

et al. 2018

View full text Add to dashboard Cite

64CuCl2 has recently been proposed as a promising agent for prostate cancer (PCa) theranostics, based on preclinical studies in cellular and animal models, and on the increasing number of human studies documenting its use for PCa diagnosis. Nevertheless, the use of 64CuCl2 raises important radiobiological questions that have yet to be addressed. In this work, using a panel of PCa cell lines in comparison with a non-tumoral prostate cell line, we combined cytogenetic approaches with radiocytotoxicity assays to obtain significant insights into the cellular consequences of exposure to 64CuCl2. PCa cells were found to exhibit increased 64CuCl2 uptake, which could not be attributed to increased expression of the main copper cellular importer, hCtr1, as had been previously suggested. Early DNA damage and genomic instability were also higher in PCa cells, with the tumoral cell lines exhibiting deficient DNA-damage repair upon exposure to 64CuCl2. This was corroborated by the observation that 64CuCl2 was more cytotoxic in PCa cells than in non-tumoral cells. Overall, we showed for the first time that PCa cells had a higher sensitivity to 64CuCl2 than healthy cells, supporting the idea that this compound deserved to be further evaluated as a theranostic agent in PCa.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiobiological Characterization of 64CuCl2 as a Simple Tool for Prostate Cancer Theranostics

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, in PCa with biochemical failure after therapy, current imaging techniques have a low detection rate at the PSA levels at which targeted salvage therapy is effective. Conventional imaging like CT has limited value for detection of recurrence in the prostatic bed after RP with a sensitivity of only 36% [72]. For detection of LN metastases the sensitivity and specificity of CT are 42% and 82%, respectively [41].…”

Section: Psma Pet In Recurrencementioning

confidence: 99%

“…For detection of LN metastases the sensitivity and specificity of CT are 42% and 82%, respectively [41]. CT is primarily able to detect large tumors, typically greater than 2 cm, and can be useful in evaluation of visceral organs and bone metastases [72]. In biochemical recurrence after primary treatment, mpMRI has a higher detection rate of local recurrence than CT, and is especially used to diagnose small local cancer recurrence in a range of PSA serum values between 0.2 and 1 ng/mL [73].…”

Section: Psma Pet In Recurrencementioning

confidence: 99%

PSMA PET and Radionuclide Therapy in Prostate Cancer

Bouchelouche

Türkbey

Choyke

2016

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Prostate cancer (Pca) is the most common malignancy in men and a major cause of cancer death. Accurate imaging plays an important role in diagnosis, staging, restaging, detection of biochemical recurrence, and for therapy of PCa patients. Since no effective treatment is available for advanced PCa, there is an urgent need to develop new and more effective therapeutic strategies. In order to optimize treatment outcome, especially in high risk PCa patients, therapy of PCa is moving rapidly towards personalization. Medical imaging, including positron emission tomography (PET)/computed tomography (CT), plays an important role in personalized medicine in oncology. In the recent years, much focus has been on prostate specific membrane antigen (PSMA) as a promising target for imaging and therapy with radionuclides, since it is upregulated in most PCa. In the prostate, one potential role for PSMA PET imaging is to help guiding focal therapy. Several studies have shown great potential of PSMA PET/CT for initial staging, lymph node staging, and detection of recurrence of PCa, even at very low PSA values after primary therapy. Furthermore, studies have shown that PSMA PET/CT has a higher detection rate than choline PET/CT. Radiolabeled PSMA ligands for therapy show promise in several studies with metastatic PCa, and is an area of active investigation. The “Image and treat” strategy, with radiolabeled PSMA ligands, has the potential to improve the treatment outcome of PCa patients, and is paving the way for precision medicine in PCa. The aim of this review is to give an overview of recent advancement in PSMA PET and radionuclide therapy of PCa.

show abstract

Genitourinary Tract Imaging

Johnson¹

2019

Medical Imaging for Health Professionals

View full text Add to dashboard Cite

State-of-the-art imaging of prostate cancer

Cited by 14 publications

References 63 publications

Radiobiological Characterization of 64CuCl2 as a Simple Tool for Prostate Cancer Theranostics

Radiobiological Characterization of 64CuCl2 as a Simple Tool for Prostate Cancer Theranostics

PSMA PET and Radionuclide Therapy in Prostate Cancer

Genitourinary Tract Imaging

Contact Info

Product

Resources

About